Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$887.16 USD

887.16
1,944,032

+1.61 (0.18%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $886.00 -1.16 (-0.13%) 6:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%

Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $329.47, marking a +0.73% move from the previous day.

Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75%

Novo Nordisk (NVO) plans to lower prices of several pre-filled insulin pens and vials by up to 75% in the United States. However, the company plans not to start this until January 2024.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK

FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $316.85 in the latest trading session, marking a +1.38% move from the prior day.

Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study

Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.

Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer

Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.

Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study

Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

Eli Lilly (LLY) closed at $318.43 in the latest trading session, marking a +1.07% move from the prior day.

NVS vs. LLY: Which Stock Is the Better Value Option?

NVS vs. LLY: Which Stock Is the Better Value Option?

United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates

United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Zacks Analyst Blog Highlights Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences

Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Tesla, Eli Lilly & Bank of America

Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Eli Lilly and Company (LLY) and Bank of America Corporation (BAC).

Pfizer (PFE) Eczema Drug Cibinqo Gets FDA Nod for Adolescents

The FDA approval for Pfizer's (PFE) Cibinqo to treat moderate-to-severe atopic dermatitis in adolescents was based on data from the phase III study, JADE TEEN.

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Sweta Killa headshot

A Look at Pharma ETFs Post Q4 Earnings

Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.